Peter J Leary1, Ryan J Tedford2, David A Bluemke3, Michael R Bristow4, Susan R Heckbert5, Steven M Kawut6, Eric V Krieger7, Joao A Lima8, Carolina S Masri7, David D Ralph7, Steven Shea9, Noel S Weiss5, Richard A Kronmal10. 1. Department of Medicine, University of Washington, Seattle, Washington. Electronic address: learyp@uw.edu. 2. Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland. 3. National Institutes of Health Clinical Center, Radiology and Imaging Sciences, Bethesda, Maryland. 4. Department of Medicine, University of Colorado, Aurora, Colorado. 5. Department of Epidemiology, University of Washington, Seattle, Washington. 6. Departments of Medicine and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 7. Department of Medicine, University of Washington, Seattle, Washington. 8. Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland; Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland. 9. Departments of Medicine and Epidemiology, Columbia University, New York City, New York. 10. Department of Biostatistics, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Myocardial H2 receptor activation may promote cardiac fibrosis and apoptosis in pre-clinical models and histamine H2 receptor antagonist (H2RA) use may improve symptoms in participants with heart failure (HF); however, relationships between H2RA use, incident HF, and longitudinal change in left ventricular (LV) morphology are not known. OBJECTIVES: This study sought to determine whether H2RA use is associated with incident HF and change in LV morphology over time. METHODS: We included 6,378 men and women from MESA (Multi-Ethnic Study of Atherosclerosis), a multicenter prospective observational cohort of participants without cardiovascular disease at baseline. Cox proportional hazards were used to estimate the association between H2RA use and incident HF in adjusted models. In participants with cardiac magnetic resonance imaging, associations between H2RA use, baseline LV morphology (n = 4,691), and longitudinal change in the LV (n = 2,806) were estimated using linear regression. RESULTS: H2RAs were used by 313 participants but not by the other 6,065 individuals. During a median follow-up of 11.2 years, 236 participants developed HF. In adjusted models, baseline H2RA use relative to nonuse was associated with 62% lower risk for incident HF (p = 0.02). H2RA use was associated with preserved stroke volume, LV end-diastolic volume, and mass/volume ratio as measured by cardiac magnetic resonance imaging over approximately 10 years (all p < 0.05). There were no associations between H2RA use and LV mass or ejection fraction. CONCLUSIONS: H2RA use was associated with reduced risk for incident HF. Left heart morphology over time suggests less age-related change in H2RA users. These associations suggest histamine signaling may be important in the pathogenesis of HF. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
BACKGROUND: Myocardial H2 receptor activation may promote cardiac fibrosis and apoptosis in pre-clinical models and histamine H2 receptor antagonist (H2RA) use may improve symptoms in participants with heart failure (HF); however, relationships between H2RA use, incident HF, and longitudinal change in left ventricular (LV) morphology are not known. OBJECTIVES: This study sought to determine whether H2RA use is associated with incident HF and change in LV morphology over time. METHODS: We included 6,378 men and women from MESA (Multi-Ethnic Study of Atherosclerosis), a multicenter prospective observational cohort of participants without cardiovascular disease at baseline. Cox proportional hazards were used to estimate the association between H2RA use and incident HF in adjusted models. In participants with cardiac magnetic resonance imaging, associations between H2RA use, baseline LV morphology (n = 4,691), and longitudinal change in the LV (n = 2,806) were estimated using linear regression. RESULTS: H2RAs were used by 313 participants but not by the other 6,065 individuals. During a median follow-up of 11.2 years, 236 participants developed HF. In adjusted models, baseline H2RA use relative to nonuse was associated with 62% lower risk for incident HF (p = 0.02). H2RA use was associated with preserved stroke volume, LV end-diastolic volume, and mass/volume ratio as measured by cardiac magnetic resonance imaging over approximately 10 years (all p < 0.05). There were no associations between H2RA use and LV mass or ejection fraction. CONCLUSIONS: H2RA use was associated with reduced risk for incident HF. Left heart morphology over time suggests less age-related change in H2RA users. These associations suggest histamine signaling may be important in the pathogenesis of HF. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
Authors: Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Richard A Kronmal; Joao A Lima; David D Ralph; Corey E Ventetuolo; Steven M Kawut Journal: Ann Am Thorac Soc Date: 2014-11
Authors: M R Bristow; N E Kantrowitz; W D Harrison; W A Minobe; W S Sageman; M E Billingham Journal: J Cardiovasc Pharmacol Date: 1983 Nov-Dec Impact factor: 3.105
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: M R Bristow; W A Minobe; M E Billingham; J B Marmor; G A Johnson; B M Ishimoto; W S Sageman; J R Daniels Journal: Lab Invest Date: 1981-08 Impact factor: 5.662
Authors: Michael A Burke; Daniel H Katz; Lauren Beussink; Senthil Selvaraj; Deepak K Gupta; Justin Fox; Sudarsana Chakrabarti; Andrew J Sauer; Jonathan D Rich; Benjamin H Freed; Sanjiv J Shah Journal: Circ Heart Fail Date: 2013-12-23 Impact factor: 8.790
Authors: Bharath Ambale Venkatesh; Gustavo J Volpe; Sirisha Donekal; Nathan Mewton; Chia-Ying Liu; Steven Shea; Kiang Liu; Gregory Burke; Colin Wu; David A Bluemke; João A C Lima Journal: Hypertension Date: 2014-06-09 Impact factor: 10.190
Authors: Peter J Leary; Edward Hess; Anna E Barón; Kelley R Branch; Gaurav Choudhary; Catherine L Hough; Bradley A Maron; David D Ralph; John J Ryan; Ryan J Tedford; Noel S Weiss; Roham T Zamanian; Tim Lahm Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405
Authors: Yoriko Heianza; Yan Zheng; Wenjie Ma; Eric B Rimm; Christine M Albert; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi Journal: Eur Heart J Date: 2019-12-14 Impact factor: 29.983
Authors: Peter J Leary; Richard A Kronmal; David A Bluemke; Peter M Buttrick; Kenneth L Jones; David P Kao; Steven M Kawut; Eric V Krieger; Joao A Lima; Wayne Minobe; David D Ralph; Ryan J Tedford; Noel S Weiss; Michael R Bristow Journal: Am J Cardiol Date: 2017-10-20 Impact factor: 2.778